	US 11,998,562 B2
	Ophthalmological formulations for the prevention of a coronavirus infection
Vijaykumar Sutariya, Tampa, FL (US); Srinivas Tipparaju, Tampa, FL (US); Kevin Sneed, Tampa, FL (US); Manas Biswal, Tampa, FL (US); Ramesh Ayyala, Tampa, FL (US); and Radouil Tzekov, Tampa, FL (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
Filed by UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
Filed on Jan. 25, 2022, as Appl. No. 17/583,781.
Claims priority of provisional application 63/141,366, filed on Jan. 25, 2021.
Prior Publication US 2022/0233564 A1, Jul. 28, 2022
Int. Cl. A61K 31/706 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01)

CPC A61K 31/706 (2013.01) [A61K 9/0048 (2013.01); A61K 31/573 (2013.01)]

18 Claims

1. An ophthalmological composition comprising a nanoparticle and ophthalmologically suitable carrier, wherein the nanoparticle comprises remdesivir, or a pharmaceutically acceptable salt thereof, in a concentration of about 15 wt %, and wherein the nanoparticle has an average diameter of from 200 to 250 nm, further wherein the nanoparticle comprises poly(lactic acid-co-glycolic-acid) carboxylic acid (PLGA-COOH).